Stocks · News reference
Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
Filed: 2026-09-15 AccNo: 0001193125-26-391880 Size: 141 KB Item 1.01: Entry into a Material Definitive Agreement
Filed: 2026-10-01 AccNo: 0001213900-26-105457 Size: 222 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Allarity Therapeutics expanded its in-house medical laboratory to include proteomics and cell line research capabilities, building on existing transcriptomics and CLIA clinical testing services. The expansion aims to deepen mechanism-of-action research for stenoparib, its dual PARP and WNT pathway inhibitor, while broadening external research services. The company expects cost efficiencies without impacting current cash runway.